Literature DB >> 35050486

Metformin exerts an antitumoral effect on papillary thyroid cancer cells through altered cell energy metabolism and sensitized by BACH1 depletion.

Yang Yu1, Chen Feng2, Jian Kuang3, Lixin Guo4, Haixia Guan5,6.   

Abstract

PURPOSE: Aberrant cell energy metabolism is one of the features of thyroid carcinogenesis. Metformin may reduce the risk of cancer, and BACH1 was reported to affect the sensitivity of cancer cells to metformin. The aims of this study were to investigate whether metformin exerts antitumor effects in PTC cells and explore the role of BACH1 depletion on the sensitivity of PTC cells to metformin.
METHODS: The viability and proliferation of PTC cell lines were analyzed with MTT and colony forming assay. Energy utilization and mitochondrial respiration were measured using Seahorse XF instruments and Mitochondrial complex-1 activity assay.
RESULTS: Our results showed the anti-proliferative and pro-apoptotic effects of metformin in PTC cells. Furthermore, metformin changed the pattern of cell energy metabolism in PTC cells, which manifested as inhibition of mitochondrial respiration, and the combination of BACH1 depletion with metformin magnified the effect of metformin alone.
CONCLUSIONS: In conclusion, metformin exerts an antitumoral effect on PTC cells both in vitro and in xenograft mouse models. A possible mechanism is through inhibiting glucose metabolism and mitochondrial respiration process. Knocking down BACH1 caused the switching of energy metabolism and sensitized PTC cells to metformin, which eventually enhanced the anti-tumor effect of metformin.
© 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  Anti-tumor; BACH1; Energy metabolism; Metformin; Papillary thyroid cancer

Mesh:

Substances:

Year:  2022        PMID: 35050486     DOI: 10.1007/s12020-021-02977-7

Source DB:  PubMed          Journal:  Endocrine        ISSN: 1355-008X            Impact factor:   3.925


  44 in total

1.  Metformin inhibits growth of thyroid carcinoma cells, suppresses self-renewal of derived cancer stem cells, and potentiates the effect of chemotherapeutic agents.

Authors:  Guofang Chen; Shuhang Xu; Kostja Renko; Michael Derwahl
Journal:  J Clin Endocrinol Metab       Date:  2012-01-25       Impact factor: 5.958

2.  Metformin and reduced risk of cancer in diabetic patients.

Authors:  Josie M M Evans; Louise A Donnelly; Alistair M Emslie-Smith; Dario R Alessi; Andrew D Morris
Journal:  BMJ       Date:  2005-04-22

3.  Metformin reduces glycometabolism of papillary thyroid carcinoma in vitro and in vivo.

Authors:  Chen-Tian Shen; Wei-Jun Wei; Zhong-Ling Qiu; Hong-Jun Song; Xin-Yun Zhang; Zhen-Kui Sun; Quan-Yong Luo
Journal:  J Mol Endocrinol       Date:  2017-01       Impact factor: 5.098

4.  Metformin inhibits growth and decreases resistance to anoikis in medullary thyroid cancer cells.

Authors:  Joanna Klubo-Gwiezdzinska; Kirk Jensen; John Costello; Aneeta Patel; Victoria Hoperia; Andrew Bauer; Kenneth D Burman; Leonard Wartofsky; Vasyl Vasko
Journal:  Endocr Relat Cancer       Date:  2012-05-24       Impact factor: 5.678

5.  Synergistic anti-proliferative effect of metformin and sorafenib on growth of anaplastic thyroid cancer cells and their stem cells.

Authors:  Guofang Chen; Diana Nicula; Kostja Renko; Michael Derwahl
Journal:  Oncol Rep       Date:  2015-02-16       Impact factor: 3.906

6.  ETS-1: A potential target of glycolysis for metabolic therapy by regulating glucose metabolism in pancreatic cancer.

Authors:  Xiu Zhang; Dan Wu; Mohanad Aldarouish; Xiaodong Yin; Chunyan Li; Cailian Wang
Journal:  Int J Oncol       Date:  2016-11-16       Impact factor: 5.650

7.  Cancer Statistics, 2017.

Authors:  Rebecca L Siegel; Kimberly D Miller; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2017-01-05       Impact factor: 508.702

8.  Induction of autophagy by ARHI (DIRAS3) alters fundamental metabolic pathways in ovarian cancer models.

Authors:  Argentina Ornelas; Christopher R McCullough; Zhen Lu; Niki M Zacharias; Lindsay E Kelderhouse; Joshua Gray; Hailing Yang; Brian J Engel; Yan Wang; Weiqun Mao; Margie N Sutton; Pratip K Bhattacharya; Robert C Bast; Steven W Millward
Journal:  BMC Cancer       Date:  2016-10-26       Impact factor: 4.430

Review 9.  Cancer burden in China: trends, risk factors and prevention.

Authors:  Dianqin Sun; He Li; Maomao Cao; Siyi He; Lin Lei; Ji Peng; Wanqing Chen
Journal:  Cancer Biol Med       Date:  2020-12-15       Impact factor: 4.248

10.  Metformin reduces thyroid cancer risk in Taiwanese patients with type 2 diabetes.

Authors:  Chin-Hsiao Tseng
Journal:  PLoS One       Date:  2014-10-10       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.